Benzinga | May 26, 2021 09:09AM EDT

Rafael Pharma Highlights Presentation Of Data On Pancreatic Cancer, Biliary Tract Cancer Candidate At American Society Of Clinical Oncology Jun. 4

Rafael Pharmaceuticals, Inc. ("Rafael" or the "Company"), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer.

"We are incredibly proud to have data to share in two hard-to-treat cancers; as challenging as the past year has been to ensure that we continue to move the needle, we have been able to make significant progress," said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. "The data continues to show us hope for the future, with our continued commitment to patients at the forefront."

Presentation Details:

Title: Abstract #TPS4158: A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)

Date: June 4, 2021

Time: 8:00 a.m. ET

Location: ASCO Meeting Library

Title: Abstract #TPS4176: A phase II open-label study of CPI-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.

Date: June 4, 2021

Time: 8:00 a.m. ET

Location: ASCO Meeting Library

"It's an honor to be able to present our ongoing research in pancreatic cancer at one of the most renowned meetings in clinical oncology. As pancreatic cancer remains a challenge for patients and clinicians, each presentation is an opportunity to share the potential for devimistat as a future treatment option," said David L. Bajor M.D., Assistant Professor, Seidman Cancer Center, University Hospitals Cleveland, Case Comprehensive Cancer Center.

"Advanced biliary cancer remains a challenge for patients and clinicians and it is crucial to continue to investigate promising novel agents, such as devimistat in this rare cancer," said Vaibhav Sahai, MBBS, M.S., Principal Investigator, University of Michigan.